MONTREAL, Oct. 2 /CNW Telbec/ - Aegera Therapeutics announced today the initiation of four new clinical oncology studies for AEG35156, a second generation anti-sense therapeutic targeting the X-Linked Inhibitor of Apoptosis (XIAP), a key member of the Inhibitor of Apoptosis protein (IAP) family.
